Platinum chemotherapy is the backbone of ovarian cancer treatment. But for far too many patients, it eventually stops working. In this episode of Power to the Patients, Brandon Li sits down with Thomas Zindrick, CEO and President of Genelux Corporation, to discuss Olvi-Vec, platinum resensitization, and why oncolytic virus therapy could give clinicians a new way to work with existing cancer treatments. Platinum resistance is one of the hardest questions to solve in clinical oncology, but some answers are beginning to emerge.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Brandon Li. Innehållet i podden är skapat av Brandon Li och inte av, eller tillsammans med, Poddtoppen.